LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA FOR CMG901
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
LEPU BIO-B: ARTICLES OF ASSOCIATION
LEPU BIO-B: List of Directors and their Roles and Functions
LEPU BIO-B: PROXY FORM FOR USE AT THE 2024 SECOND EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: (1) PROPOSED RE-ELECTION OF THE BOARD OF DIRECTORS; (2) RETIREMENT OF CO-CHIEF EXECUTIVE OFFICER AND DIRECTORS; (3) PROPOSED RE-ELECTION OF SUPERVISORS; AND (4) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
LEPU BIO-B: PROXY FORM FOR USE AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: Notification Letter with Request Form to Non-Registered Shareholders
LEPU BIO-B: Notification Letter with Request Form to Registered Shareholders
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT OF PIVOTAL PHASE IIb CLINICAL TRIAL FOR MRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT ORPHAN-DRUG DESIGNATION GRANTED BY THE FDA TO MRG004A FOR THE TREATMENT OF PANCREATIC CANCER
LEPU BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
LEPU BIO-B: VOLUNTARY ANNOUNCEMENT FAST TRACK DESIGNATION GRANTED BY THE FDA TO MRG003 FOR THE TREATMENT OF R/M NPC
LEPU BIO-B: PROXY FORM FOR USE AT THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
LEPU BIO-B: (1) RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION; AND (3) NOTICE OF THE 2023 SECOND EXTRAORDINARY G
No Data